| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-07-01 |
| タイトル |
|
|
タイトル |
Effectiveness of Hangeshashinto in delaying grade 2 radiotherapy-induced mucositis development in patients with hypopharyngeal or laryngeal cancer: Preliminary finding of a randomized clinical trial |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Hangeshashinto (TJ-14) |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
head and neck cancer |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
mucositis |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
radiotherapy |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
randomized clinical trial |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Kawashita, Yumiko
Umeda, Masahiro
Murata, Maho
Yoshimatsu, Masako
Shiraishi, Chiaki
Omori, Aya
Yamazaki, Takuya
Nishi, Hideaki
Soutome, Sakiko
Ukai, Takashi
Toya, Ryo
Kumai, Yoshihiko
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: The efficacy of Hangeshashinto (TJ-14) during radiotherapy administration in patients with head and neck cancer remains unknown. We investigated the effectiveness of TJ-14 in delaying grade 2 radiotherapy-induced mucositis development in patients with hypopharyngeal or laryngeal cancer. Methods: The trial involved 28 participants, allocated in a 1:1 ratio, to either the control or intervention group using a stratified randomization method adjusted for primary cancer location and treatment type. Results: Kaplan–Meier curves showed that the 50% incidence rate of grade 2 pharyngeal mucositis between the intervention and control group (46 Gy vs 34 Gy, P = .49). Six participants in the intervention group stopped taking TJ-14 during the development of grade 1 pharyngeal mucositis (mean oral medication period: 2.7 days). Conclusion: The findings of this single-center randomized clinical trial showed that taking TJ-14 from the onset of grade 1 mucositis tended to delay the development of grade 2 mucositis. However, patient compliance was poor in the intervention group. Therefore, multicenter randomized controlled trials should be planned with considering the low compliance of this population to understand the effectiveness of TJ-14. Abbreviations: CTCAE v.5.0 = the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, TJ-14 = Hangeshashinto. |
|
言語 |
en |
| 書誌情報 |
en : Medicine
巻 104,
号 24,
p. art. no. e42870,
発行日 2025-06-13
|
| 出版者 |
|
|
出版者 |
Wolters Kluwer Health, Inc |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1536-5964 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1097/MD.0000000000042870 |
| 権利 |
|
|
権利情報 |
© 2025 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CC BY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Medicine, 104(24), art. no. e42870; 2025 |
|
言語 |
en |
M104_e42870.pdf (626 KB)
